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Determining the phenotype of patient RBCs that are positive by the
DAT may prove problematic. Antigen typing of RBCs coated with
IgG requires direct agglutinating reagents or chemical treatment
(such as chloroquine diphosphate [CDP] or citric acid) to remove
sufficient IgG to permit testing with IAT-reactive reagents. The
citric acid elution method is commonly used in the United States;
however, antigens in the Kell system are altered to the extent that
they may appear to be absent by this method. There are a limited
number of direct agglutinating monoclonal antibodies available.
Murine monoclonal antibodies provide an additional tool for typing
RBCs with a positive DAT. Five murine monoclonal IgG antibodies
(anti-K: MIMA-22, MIMA-23; anti-Kpa: MIMA-21, MIMA-27; anti-Fya:
MIMA-19) were used in this study. Donor RBCs with known
phenotypes were sensitized in vitro with alloanti-D, alloanti-c, and
alloanti-K and with 20 autoantibodies (autoanti-D [n=3], autoanti-e
[n=5], autoanti-Ce/e [n=5], autoanti-e+D+E [n=1], autoanti-I [n=1],
and nonspecific [n=5]) to simulate a positive in vivo DAT. The
sensitized RBCs were treated with CDP to remove IgG. To
determine the efficacy of the murine monoclonal antibodies when
testing DAT-positive samples, both sensitized and CDP-treated RBCs
were tested with these monoclonal antibodies by the IAT using
anti-mouse IgG. No discrepancies were noted with the
unsensitized, sensitized, or CDP-treated RBCs. An exception was
noted with a potent autoanti-I, where direct agglutination of the
sensitized RBCs was obtained.This study demonstrates the value of
using murine monoclonal antibodies to determine the phenotype
of RBCs with a positive DAT caused by autoantibodies (e.g., in
autoimmune hemolytic anemia) and supports previous studies
showing that RBCs sensitized in vivo can be typed without
chemical manipulation. Immunohematology 2006;22:161–165.
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Determining an accurate RBC phenotype for
patients whose RBCs are positive by the DAT can be
problematic because these RBCs are already coated in
vivo with immunoglobulin, complement, or both; all
tests performed will be positive by IAT with antihuman
IgG reagents. There are very few IgM directly
agglutinating reagents available for the clinically
significant antibodies (i.e., anti-K, -Jka, -Jkb, -S, and -Fya).
One option is to chemically treat the DAT-positive RBCs
to remove IgG autoantibodies. These treatments may
use chloroquine diphosphate (CDP), a combination
enzyme/reducing agent (ZZAP, National Blood Service
Reagents,Birmingham,UK) which is composed of DTT
and papain, or EDTA/citric acid (Elu-Kit II, Gamma
Biologicals, Inc., Houston, TX). Several other methods
are available to remove the antibody for serologic
testing; however the RBCs are not suitable for testing
after these treatments.1–5
CDP and enzyme/reducing agent (ZZAP, National
Blood Service Reagents) treatments can cause damage
to the RBCs, resulting in the loss of some RBC antigens
and possible invalid typing results.6–8 Additionally, CDP
may not totally remove the coating autoantibody from
the RBCs and it does not remove complement
component 3 (C3).1 The proteolytic enzyme,papain, in
the enzyme/reducing agent product denatures some
MNS and Duffy antigens. The reducing agent, DTT,
denatures the antigens in Kell and Yt systems among
others. RBCs treated with the reagent combining both
these chemicals (ZZAP, National Blood Service
Reagents), therefore, have limited applications for use
in phenotyping studies.9 The citric acid elution
method is commonly used in the United States, a major
drawback being that antigens of the Kell system are
significantly weakened by this method. The
development of murine monoclonal antibodies has
provided an additional tool to allow DAT-positive RBCs
to be antigen typed.10,11
Materials and Methods
Selected patient samples containing alloantibodies
and autoantibodies were obtained from the samples
routinely referred to the Red Cell Immunohaematology
Laboratory, National Blood Service, Colindale Centre,
UK. Samples from three antenatal women with high
titers of anti-D, -c, and –K, respectively, were selected
for testing. A total of 20 autoantibodies from patients
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with autoimmune hemolytic anemia (AIHA) were also
selected:anti-D (n=3),anti-e (n=5),anti-Ce/e (n=5),anti-
e+D+E (n=1), anti-I (n=1), and nonspecific (n=5).
(See Table 1 as an example of phenotyping results
using murine monoclonal antibodies with
unsensitized, sensitized, and CDP-treated RBCs for
sample 2). All samples were collected in EDTA and
were tested within 5 days of collection. The murine
monoclonal antibodies used included MIMA-19:
(anti-Fya), MIMA-21: (anti-Kpa), MIMA-22:
(anti-K), MIMA-23: (anti-K), and MIMA-27:
(anti-Kpa). Ten different commercial human
monoclonal antibodies were also tested;
anti-C, -c, -E, and -e (MS-24, MS-33, MS-258/
906, MS-16/MS-21/MS-63 respectively,
Biotest AG, Dreiech, Germany); anti-Cw, -Jka,
-Jkb, and -S (MS-110, MS-15, MS-8, MS-94
respectively, Serologicals Ltd., Livingston,
Scotland), anti-K (MS-56, Lorne Laboratories,
Reading, UK), and anti-Fya (5T72, Bio-Rad,
Marines La Coquette, France).
Sensitization of donor RBCs
Aliquots of 500 µL of washed, packed
RBCs from nine donors (R1R1 [n=3], R2R2
[n=3], and rr [n=3]) were each incubated
with 500 µL of the alloantibody or the
autoantibody at 37°C for 60 minutes.
Sensitized RBCs were confirmed by
obtaining a positive DAT using polyspecific
antihuman reagent (AHG, Lorne
Laboratories).
CDP treatment
CDP (200 mg/mL,pH 5.0 ± 0.1,National
Blood Service Reagents) was used to treat
RBCs with a positive DAT. Four volumes of
CDP were added to 1 volume of washed
(×4) DAT-positive packed RBCs, mixed, and
incubated at 20°C for a maximum of 2
hours. The strength of the DAT was tested
after a 30-minute incubation at 37°C using a
monospecific antihuman reagent (anti-IgG,
Biotest AG).
Hemagglutination testing
All of the treated RBC samples were
washed 4 times with 0.9% PBS and
resuspended in a low ionic strength
solution (LISS, Inverclyde Biologicals,
Bellshill, Scotland) at a 2% suspension. Both treated
and untreated RBCs were tested with murine
monoclonal antibodies by IAT (40 µL:40 µL) and
incubated at 20°C for 30 minutes using a sheep-derived
IgG reagent directed at mouse IgG (sheep-anti-mouse
IgG,The Binding Site, Birmingham,UK, code PC271.X).
The sheep-derived reagent was diluted at a ratio of 1 in
50 in a bovine serum albumin solution (1% BSA,
Serologicals, Kankakee, IL) in PBS.
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Table 1. An example of phenotype results of murine monoclonal antibodies with
unsensitized, sensitized, and CDP-treated RBCs (Sample 2)*
Rh K Fya Kpa
Donor 1 R1R1 + + 0 Unsensitized 4 4 4 0 4 NT 0 0
Sensitized 5 4 3 0 3 NT 0 4
CDP treated 5 4 3 0 4 NT 0 0
Donor 2 R1R1 + + 0 Unsensitized 4 4 3 0 5 NT 0 0
Sensitized 5 4 3 0 3 NT 0 4
CDP treated 5 2 3 0 4 NT 0 0
Donor 3 R1R1 + 0 0 Unsensitized 4 0 0 0 5 NT 0 0
Sensitized 5 4 0 0 3 NT 0 4
CDP treated 5 0 0 0 3 NT 0 0
Donor 4 rr + 0 0 Unsensitized 4 0 0 0 5 NT 0 0
Sensitized 5 4 0 0 3 NT 0 4
CDP treated 5 0 0 0 4 NT 0 0
Donor 5 rr + + 0 Unsensitized 4 3 3 0 5 NT 0 0
Sensitized 5 4 2 0 3 NT 0 4
CDP treated 5 4 3 0 4 NT 0 0
Donor 6 rr + + 0 Unsensitized 4 4 3 0 5 NT 0 0
Sensitized 5 4 2 0 3 NT 0 4
CDP treated 5 4 3 0 4 NT 0 0
Donor 7 R2R2 + + 0 Unsensitized 4 4 4 0 5 NT 0 0
Sensitized 5 4 3 0 3 NT 0 4
CDP treated 5 3 3 0 4 NT 0 0
Donor 8 R2R2 + + 0 Unsensitized 4 4 3 0 5 NT 0 0
Sensitized 5 4 3 0 3 NT 0 4
CDP treated 5 3 3 0 4 NT 0 0
Donor 9 R2R2 + + 0 Unsensitized 4 3 3 0 5 NT 0 0
Sensitized 5 4 3 0 3 NT 0 4
CDP treated 5 3 3 0 4 NT 0 0
*Grading per system for hemagglutination used by Red Cell Immunohaematology Laboratory, National
Blood Service, Colindale Centre, UK
5 Cell button remains in one clump or dislodges into a few large clumps,macroscopically
visible
4 Cell button dislodges into numerous large clumps,macroscopically visible
3 Cell button dislodges into many clumps,macroscopically visible
2 Cell button dislodges into finely granular but definite small clumps,macroscopically visible
1 Cell button dislodges into very small agglutinates; these are more distinct if the tube is left
on its side to allow the cells to settle,macroscopically visible
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Adsorption and elution
Two mL of donor RBCs were washed 3 times in
PBS, added to 2 mL of sensitizing antibodies, and
incubated at 37°C for 60 minutes. To ensure
sensitization, a DAT was performed on the sensitized
RBCs with polyspecific antihuman reagent (AHG,Lorne
Laboratories). An eluate was prepared using an
EDTA/citric acid kit (Elu-Kit II, Gamma Biologicals,
Inc.). The eluate and last wash were each tested by IAT.
Validation by flow cytometry
The five murine monoclonal antibodies (MIMA-19,
MIMA-21, MIMA-22, MIMA-23, and MIMA-27) were
validated by flow cytometry. To validate the tests, 4 µL
of packed unsensitized, sensitized (DAT-positive), or
CDP-treated RBCs were added to 40 µL of MIMA-19,
MIMA-23, MIMA-21, MIMA-22, and MIMA-27 in plastic
tubes. After 30-minute incubation in a 37°C water
bath, the tubes were washed 3 times with 0.9% PBS.
Fifty µL of FITC-conjugated F(ab′)2 goat-derived reagent
directed at mouse immunoglobulin (goat anti-mouse
immunoglobulin DAKO A/S, Denmark, code F0479)
was added and the tubes were incubated for 30
minutes at 37°C in the dark. The mixture was washed
twice and resuspended in 1% BSA in PBS. The tubes
were analyzed by a flow cytometer (FACSCAN, Becton
Dickinson,Oxford, UK)
Results
Adsorption and elution validation demonstrated
autoantibodies that were successfully bound to the
donor RBCs and could be eluted off. Flow cytometry
results confirmed the selected murine monoclonal
antibodies bound specifically to target antigens with
unsensitized, sensitized, and CDP-treated RBCs. (See
Figures 1a-c.) No nonspecific binding was observed
with antigen-negative donor RBCs. (Results not
shown).
Table 1 shows the phenotyping results of sample 2
(allo anti-K) using murine monoclonal antibodies with
unsensitized, sensitized, and CDP-treated RBCs from
nine donors (3 × rr, 3 × R1R1, and 3 × R2R2). Post
sensitization, all of the donor’s RBCs were positive by
the DAT which confirmed that the donors’ RBCs were
coated with the sensitizing antibody in this study. No
discrepant results were observed with the murine
monoclonal antibodies tested. However, there was
insufficient anti-K (MIMA-23) for testing samples
number 1 to 3. The false positive reactions with the
RBCs from donors 3 and 4 using IgG monoclonal
IAT-reactive anti-Fya were not surprising. As the
postsensitized donor RBCs were DAT positive, a false
positive result would be expected by IAT.
A summary of the phenotyping results for all
antibodies tested is shown in Table 2 (actual results not
shown). There were no discrepant results obtained
with the murine monoclonal antibodies used; however,
false positive reactions were obtained with commercial
anti-sera and are shown in the Results column.
The test results with unsensitized, sensitized, and
CDP-treated RBCs were concordant with one
exception: a potent autoanti-I caused direct
agglutination of all RBC samples.
Monoclonal antibodies for RBC phenotyping
Fig. 1. Binding of MIMA-23 (anti-K) with unsensitized, sensitized, and
CDP-treated K+k+ RBCs. (A) MIMA-23 versus unsensitized K+k+
RBCs; (B) MIMA-23 versus sensitized K+k+ RBCs; (C) MIMA-23
versus. sensitized and chloroquine-treated K+k+ RBCs.
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Conclusion
In this study, no discrepancies were noted when
the murine monoclonal antibodies were tested with
unsensitized, sensitized, and CDP-treated RBCs
(alloantibodies [n=3],autoantibodies [n=20]). The only
exception was a potent autoanti-I that caused direct
agglutination of all RBCs, as would be expected.
Commercial human monoclonal IgM reagents (anti-K,
-Jka, -Jkb, and -S) can produce false positive reactions so
it is important to test a low-protein diluent control in
parallel with the test as suggested by manufacturers to
validate the test results. Polyclonal phenotyping
antisera derived from a human source are IAT reactive.
The RBCs coated with IgG will give a positive result,
using the IAT, which accounted for the false positive
reactions.
Although previous studies have shown that
phenotypes of RBCs sensitized in vivo by alloantibodies
can be determined using murine monoclonal
antibodies, the nature and characteristics of autoanti-
bodies present in a patient’s serum may be quite
different.10 In this paper,we demonstrated that murine
monoclonal antibodies may be used without pretreating
the RBCs with enzymes or chemicals. Furthermore,
they provide accurate, reproducible results. In
summary, murine monoclonal antibodies used in this
study and in previous studies show that these
antibodies can be used to determine the phenotype of
patient RBC samples that are DAT positive, thus saving
money and time and improving patient care.
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